Table 1.
Clinical featuresa
| Parameter | Ketamine+(n = 20) | Ketamine−(n = 20) | P |
|---|---|---|---|
| Age (yr) | 39 (32 to 50) | 42 (32 to 50) | 0.95 |
| BMI (kg/m2) | 22.5 (20.6 to 26.2) | 22.3 (20.5 to 26.2) | 0.89 |
| Baseline creatininemia (μmol/L) | 61.0 (56.8 to 64.2) | 59.5 (52.0 to 64.0) | 0.86 |
| MDRD eGFR (ml/min per 1.73 m2) | 100 (95 to 117) | 107 (89 to 125) | 0.79 |
| H0 MAP (mmHg) | 97 (88 to 103) | 93 (80 to 110) | 0.37 |
| H1 MAP (mmHg) | 83 (73 to 90) | 83 (72 to 93) | 0.97 |
| H0 UAlb/UCreat (mg/mmol) | 0.8 (0.5 to 1.3) | 0.7 (0.5 to 1.5) | 0.64 |
aCharacteristics of patients, according to the use of ketamine. Data are median (25th to 75th percentiles). Values in Ketamine+ and Ketamine− groups are compared by Mann-Whitney U test. eGFR, estimated GFR; MAP, mean arterial pressure.